



Estd 1992 E- NEWSLETTER

(Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and Pharmacy Council of India)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA

Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org

E-mail: bpharmchopda@yahoo.com

NEWSLETTER 2014-2015

(For Internal Circulation Only)

EDITORIAL BOARD

Dr. A.V.Patil

Dr.J.C.Hundiwale

Dr. B.S.Sathe

NEWS LETTER CO-ORDINATOR

Mr. Bharat Jain.

Mrs. P.N. Jadhav

GUEST DESK: Dr. Tanaji Talele Professor of Medicinal Chemistry New-York, U.S.A

It gives me pleasure to know that a team of Smt.Sharadchandrika Suresh Patil Pharmacy Collage is publishing News letter.I am happy to understand that the collage is contributing to the need of Healthcare system, Pharmaceutical industries, Research & Development & Pharma Education of the country through its students who come out successfully. I am also sure that this collage News letter will represent the spirit, technical & literary talent hidden of the students & staff of the collage to share their views. I would like to convey my heartiest wishes on the occasion of the release of the said magazine.

OUR AFFILIATION

North Maharashtra University was established on August 15, 1990 In 2001, NAAC Accredited the prestigious 4 Star Status to the University. The university was reaccredited by NAAC as 'B' (CGPA 2.88 on 4 point scale) grade university. Currently during the third cycle of accreditation by NAAC, the University has been awarded with 'A' grade (CGPA 3.05 on 4 point scale). A splendid, unique & excellent multi professional education campus promoted by the NMU.



PRESIDENT DESK

Hon. Adv.Bhaiyasaheb Sandeep Suresh Patil President, MGSM, Chopda


that Smt.S.S.Patil collage of pharmacy is bringing out a vsletter. The college Newsletter will definitely help to showcase the activities that are happening in the campus. It also helps in building up teamwork which is very much needed today in the world of competition. This enhances the documentation culture of the institute. I hope that this culture of releasing Newsletter continue for ever and become a quoted example for all other colleges to follow.

PRINCIPAL DESK

Dr. G.P.Vadnere Principal

t gives me immense pleasure to extend a warm welcome smt.S.S.Collage of Pharmacy chopda. I hope this website server as a useful source of information for Prospective students, health care professional, alumnus, friends and the general public. I would like to express my considerable appreciation to all contributors in this issue of the News letter. These contributions have required a generous contribution of time and effort. Thank you all!!







E- NEWSLETTER

(Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and Pharmacy Council of India)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA

Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org
E-mail: bpharmchopda@yahoo.com

OUR INSTITUTION

Smt. Sharadchandrika Suresh Patil College of Pharmacy Chopda was established in 1992 as self financed pharmacy college in the North Maharashtra University, (NMU) Jalgaon. The institution has made a steady progress during last 24 years. In the year 2006 with the intention of making this institution a centre of higher learning, started M. Pharm. in Pharmaceutics (2006) later M. Pharm in Pharmacognosy (2007) and centre for Ph. D. in Pharmaceutical Sciences (2011). All the courses conducted in this Institution are recognized by Pharmacy Council of India, New Delhi, All India Council for Technical Education, New Delhi. B. Pharm., M. Pharm. and Ph. D. courses are affiliated to North Maharashtra University, (NMU) Jalgaon. Recently (2014) Institute has been certified An ISO 9001-2008 for quality management services. The collage spread over more than 9.168 acres of land is a part of the MGSM campus. The collage campus also includes hostel, staff quarters, central dispensary, sports complex, guest house etc.

GUEST DESK: Machhindra D.Bochare. Dept.Of Pharmaceutical science &Technology Matunga, Mumbai.

I am Extremely Happy to know that a team of Smt.S.S. Patil Pharmacy collage publishing News letter. The symposium will provide a platform to improve the quality of education & in turn this would definitely create an impact in the minds of readers, by way of providing larger visibility and dimension to the campus. I am confident that the teaching staff understand the needs of future & SSPCOP would deliver time tested human resource to meet the requirement of pharmacy profession & society in years to come. I congratulate the principal, staff & students for publishing News letter 2014-15. My good wishes to you & hope that this issue of News letter would be meaningful, enjoyable & memorable in achieving its Objectives.

COORDINATOR: Prof. BHARAT JAIN



I present this Pharma newsletter to you with fervent hope that you love to go through the same with interest, not only for its regular contents and activities and achievements but also for its tiny chunks of wisdom quotes related to health and pharmacy, apart from other interesting matters, which try to serve as magical bits of potions to uplift thespirit.



ASSISTANT COORDINATOR: Prof. Prerana Jadhav.

It gives me great opportunity to present the issue of News letter, the measure of progress. This news letter was one such cherished work that had its roots in the persuasion. It would be a snapshot of the various activities and advancements for all associated with Smt.S.S. Patil collage of pharmacy. This maiden issue of newsletter should inspire all of us for a new beginning enlighten with hope, confidence and faith in each other in the road ahead..... Happy Reading!





Estd 1992
E- NEWSLETTER

(Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and Pharmacy Council of India)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA

Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org
E-mail: bpharmchopda@yahoo.com

OUR ACADEMIC STARS(2014-2015)

First Year B.Pharm.(Sem-II) CGPA

First



Ghait Vikas N. 7.73 Grade

Second



Ghuge Prasannakumar R. 7.58 Grade

Third



Nerpagar Dipak K. 7.50 Grade

Second Year B.Pharm(Sem-IV) CGPA

First



Patil Dharamraj P. 8.18 Grade

Second



Patil Nilima C. 8.11 Grade

Third



Patil Bhavana I. 8.00 Grade

Third Year B.Pharm(Sem-VI) CGPA

First



Deshmukh Preeti 7.96 Grade

Second



Patil Rahul Dilip 7.88 Grade

Third



Patil Poonam 7.62 Grade





Estd 1992 E-NEWSLETTER.

> (Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and **Pharmacy Council of India**)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA

Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org E-mail: bpharmchopda@yahoo.com

Final Year B.Pharm (sem-VIII) CGPA

First



Patil Namrata 75.4%

Second



Patil Leena 74.4%

Third



Patil Valmik 74.2%

1st Year M. Pharm. Pharmaceutics (Sem. II)

1st Year M. Pharm. Pharmacognosy(Sem-II)

First



Warule Kanchan A. Patil Yogesh C. 69.2%

Second



64.4%

Third



Jain Priti V. 62.8%

First



Chavan Piyush K. 59.4%

GPAT 2015 QULIFIED STARS



Patil Lina



Patil Valmik



Patil Ashwini





Estd 1992
E- NEWSLETTER

(Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and Pharmacy Council of India)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA

Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org
E-mail: bpharmchopda@yahoo.com

RESULT ANALYSIS 2014-2015

Sr No.	Class	Total no.of Student Appeared	Total no. of student passed	% Result
1	First Year B.pharm	59	52	88.13%
2	Second year B.pharm	68	62	91.17%
3	Third Year B. Pharm	71	67	94.36%
4	Final Year B. Pharm	68	57	83.82%

Participated and Presented In Conference/Seminar



Chairperson for one day National workshop sponsored by NMU at A.R.A. College of Pharmacy, Dhule



Prof.Bharat Jain conferred with Young Talent Award 2015 in International Conference at DIT University, Deharadun, Uk on 27-28 Feb. 2015



Prof.Ragib Shaikh conferred with Young Pharmacist Award 2015 in National convention held at Invertis University, UP.





(Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and Pharmacy Council of India)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA

Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org
E-mail: bpharmchopda@yahoo.com

EXTRA CO-CURRICULAR ACTIVITIES













Biotech Grant Program announced by Merck Millipore

Issue: March 24, 2015

Committed to helping advance lifesaving drugs to market, Merck Millipore hosted its first emerging biotech grant program last year, awarding one company up to \$89,000 in products and services to help develop their molecule. NGM Biopharmaceuticals, Inc. was selected as the 2014 recipient. The company, based in San Francisco, was chosen in accordance with the contest rules. Decision-making criteria included the scientific and societal merit of the therapy being developed, and process challenges and expertise gaps associated with the development of the therapy.NGM Biopharmaceuticals, is an innovative drug discovery company engaged in identifying and developing biologics for the treatment of cardio-metabolic conditions, bile acid-related disease, and potentially other diseases resulting from manifestations of cardio-metabolic abnormalities and metabolic related cancers. It is hope that with the use of Merck Millipore's tools and services, they will be able to help advance the manufacturing of their biologics.





Estd 1992
E- NEWSLETTER

(Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and Pharmacy Council of India)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA

Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org

E-mail: bpharmchopda@yahoo.com

Remaining committed to the Emerging Biotech market, Merck Millipore is hosting an exclusive Emerging Biotech Executive Summit this June where industry and Merck Millipore executives will network and join

panel discussions around Perspectives on Early Stage Investments and Partnerships, and Building Value, Credibility and Recognition on the Road to Clinic.

M. PHARM(IV SEM) STUDENTS THESIS M.Pharm (Pharmaceutics)

Sr	Name of students	Title of Thesis	Guide
no.			
1	Mr.Amol R. Patil	Formulation & Evaluation of Controlled release tablet of Dronedarone HCL	Dr. S.M. Sarode
2	Mr.Nayansingh V. Rajput	Formulation, Evaluation & process parameter optimization for fast dissolving Sublingual film of Anti-asthamatic drug	Dr. P. V. Jain
3	Mr. Nitin V. Valvi	Formulation & Development of Controlled release tablet of Anti-epileptic drug	Dr. P .V. Jain
4	Mr. Rohit S. Patil	Formulation & Evaluation of Taste masked Orodispersible tablet.	Dr. S. M. Sarode
5	Mrs. Chaitali D. Patil	Preparation & In-vitro Evaluation of Sustained release tablet of Trimetazinide dihydrochloride.	Dr. P.V. Jain
6	Mr.Dhananjay S. Wagh	Formulation ,Development & Evaluation of Mucoadhesive buccal tablet for Oral Candidiasis.	Dr. P. V. Jain
7	Mr. Nikhilsingh N. Rajput	Design, Development & Evaluation of Orodisperisble tablet of Anti-asthamatic agent	Dr. S. M. Sarode
8	Mr.Vishal B. Patil	Microwave Generated bionanocomposite for enhancement of solubility & dissolution of poorly water soluble drugs.	Dr. S M. Sarode
9	Miss. Ashwini A. Mahajan	Formulation & Evaluation of Nevirapine Nanoparticles	Dr. S. M. Sarode.
10	Mr. Digvijay A. Salunkhe	Formulation & Evaluation of Sustained release Matrix tablet.	Dr. P. V. Jain

M.Pharm (Pharmacognosy)

1	MR. Hemant K.	Phytochemical & Pharmacological Evaluation of	Dr. A. V. Patil
	Chaudhari.	flowers of Veroaia cineea linn	
2	Mr. Prasad S. Sonwane	Phytochemical & Pharmacological investigation	Dr. A. V. Patil
		of Tubernaemontana divaricata	

New global website

It is pleased to announce the launch of new website – **www.merckmillipore.com**. It listened to your feedback and have developed an improved user experience, with even better ways to access





E-NEWSLETTER

(Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and Pharmacy Council of India)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA

Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org

E-mail: bpharmchopda@yahoo.com

information. This global website is about delivering on their brand promise: innovation, collaboration and reliability – it shows theire commitment to making it easy for you to do business with them. This means easier browsing of our product portfolio in the context of your work. With a new structure arranged according to your processes and production steps, you can quickly access what you need. Whether it's learning about innovative products, downloading key documents, getting help from our customer service team or watching webinars on demand, our new site will support your efforts in research, development and production.

They welcome you to explore and see for yourself how Merck Millipore has improved your browsing experience

The Novel New Drugs of 2014

Drug Name	Active Ingredients	Approval Date	What it is used for
Opdivo	Nivolumab	12/22/2014	To treat patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who no longer respond to other drugs.
Rapivab	Peramivir	12/19/2014	To treat influenza infection in adults.
Zerbaxa	ceftolozane/ tazobactam	12/19/2014	To treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
Lynparza	Olaparib	12/19/2014	To treat advanced ovarian cancer.
Esbriet	Pirfenidone	10/15/2014	For the treatment of idiopathic pulmonary fibrosis (IPF).
Lumason	sulfur hexafluoride lipid microsphere	10/10/2014	For patients whose ultrasound image of the heart (echocardiograms) are hard to see with ultrasound waves.
Trulicity	Dulaglutide	9/18/2014	To treat adults with type 2 diabetes.
Belsomra	Suvorexant	8/13/2014	To treat difficulty in falling and staying asleep (insomnia).
Orbactiv	Oritavancin	8/6/2014	To treat adults with skin infections.
Striverdi Respimat	Olodaterol	7/31/2014	To treat chronic obstructive pulmonary disease.

 $Source\hbox{-}www.fda.gov$

Breakthrough Diabetes Treatment

As reported in August 2014 from research in *The Lancet Diabetes & Endocrinology*, the vast majority of people with type 2 diabetes are living longer lives due to better medications and treatments for both the disease and the numerous complications that result from type 2 diabetes.

Afrezza:





(Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and Pharmacy Council of India)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org

E-mail: bpharmchopda@yahoo.com

Afrezza (insulin human) Inhalation Powder was **approved** by the FDA in June 2014. Afrezza is an ultra rapid-acting inhaled insulin that is administered with meals to improve glycemic control in adult diabetics. In clinical trials, Afrezza was evaluated in 24-week studies in both type 1 and type 2 diabetic patients. In 1,026 type 1 patients also using long-acting insulin, Afrezza effectiveness to lower blood sugar (A1c) provided less A1c reduction than **insulin aspart** (an injectable fast-acting insulin), and the difference was statistically significant. In 1,991 type 2 patients also using oral antidiabetic agents, inhaled Afrezza did significantly lower A1c compared to a placebo group (also using oral antidiabetics) in a 24-week study. Afrezza, because it is inhaled and not injected, may cause the serious side effect of bronchospasm in patients with asthma or chronic obstructive pulmonary disease (COPD), and should not be used in these patients. The most common adverse reactions associated with Afrezza in clinical trials were hypoglycemia (low blood sugar), cough, and throat pain or irritation.

Finding new antibiotics

2 July 2014 The prime minister has called for global action to tackle the threat of resistance to antibiotics. In a BBC interview, David Cameron will announce a review to identify why the market has failed to deliver new drugs and to formulate proposals to take to the G7 next year. Below are two viewpoints on the issue.

Peter Taylor, Professor of Microbiology, UCL School of Pharmacy


His MRC-funded research is focused on finding novel anti-microbial agents - from identifying phages - the viruses that attack bacteria to developing compounds which disable rather than kill microbes - leaving them vulnerable to attack from other drugs or the body's own defences. They are trying to take a different approach - to disarm the bacteria - modify them in such a way that they are no longer able to cause infection and this strategy does work, They have shown this in a number of models of infection & found that some components in Japanese green tea are able to insert into the membranes of strains of MRSA - the superbug which causes very many lethal infections in hospitals. It basically converts the bacteria from being fully resistant to front line drugs - the cephalosporin's and the penicillin's - to make them become completely susceptible to these drugs.

The idea is they can use these agents alongside conventional drugs that have lost their utility because of the emergence of resistance.

Patrick Vallance, President of R&D, GlaxoSmithKline

His company has spent around a billion dollars researching new antibiotic agents over the last decade, but admit they have very little in the way of new drugs to show for their investment. They have spent something like a \$1bn over the last 10-12 years on antibiotic research and development. They have one drug come through for skin infections which is licensed and a couple in the late stage pipeline now and they've got some earlier things but you know that's a lot of money to spend. New antibiotics as compared with an old antibiotic? Pennies. So the price is very different for the two and of course it is a very short







Estd 1992
E- NEWSLETTER

(Affiliated to North Maharashtra University, approved by Govt. of Maharashtra, AICTE and Pharmacy Council of India)

CHOPDA-425107 DIST.JALGAON (M.S.), INDIA

Phone / Fax No. - +91-2586-222366/Visit us: www.pharmacychopda.org

E-mail: bpharmchopda@yahoo.com

treatment duration very often but it can have equally big effects so there is this disparity in how society values the two types of medicines.